Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15.

13 Sep 2010

DARA BioSciences presents KRN5500 study results at World Congress on Pain

DARA BioSciences announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind, randomized dose escalation study for KRN5500 at the 13th World Congress on Pain held recently in Montreal.

9 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

Research finds immune system mechanism to minimize collateral damage

A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.

3 Sep 2010

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to findings from the University of Alabama at Birmingham published online today at Science Express.

3 Sep 2010

NIH awards $1.2 million EUREKA grant to study protein misfolding

Three University of Massachusetts Amherst scientists have received a four-year, $1.2 million EUREKA grant from the U.S. National Institutes of Health (NIH) to study folding and misfolding of secretory proteins in the cell's protein factory, the endoplasmic reticulum, where misfolding can lead to diseases such as cystic fibrosis and liver cirrhosis.

3 Sep 2010

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.

2 Sep 2010

Luminex launches FDA-cleared xTAG Cystic Fibrosis 60 Kit v2 diagnostic test

Luminex Corporation, the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG Cystic Fibrosis 60 Kit v2, a new diagnostic test that can simultaneously screen a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

From Thermo Fisher Scientific Inc. 27 Aug 2010

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

Vitamin D may be an effective therapy to treat and even prevent allergy to a common mold that can cause severe complications for patients with cystic fibrosis and asthma.

26 Aug 2010

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.

26 Aug 2010

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.

25 Aug 2010

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

Cryo-Cell International, Inc., one of the largest and most established leaders in stem cell innovation, today announced a research and development collaboration agreement with Monash University in Australia. The partnership will allow scientists from the University's Centre of Inflammatory Diseases to conduct pre-clinical studies using Cryo-Cell's proprietary C'elle menstrual stem cell technology (MenScs) to identify potential future therapies to treat autoimmune diseases such as multiple sclerosis.

18 Aug 2010

LevPharm to distribute Innovotech's bioFILM PA- test in Israel

Innovotech Inc., a pioneer in the field of biofilm product development, has signed an exclusive distribution agreement with LevPharm Ltd of Israel to market and distribute its bioFILM PA- test to hospitals and clinics within Israel.

13 Aug 2010

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Genta Incorporated today announced financial results for the quarter ending June 30, 2010.

12 Aug 2010

Aradigm reports net loss of $4.1M for second-quarter 2010

Aradigm Corporation today announced financial results for the second quarter and six months ended June 30, 2010.

12 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

GenMark second-quarter revenues increase 162% to $651,000

GenMark Diagnostics, Inc. today reported revenues of $651,000 for the quarter ending June 30, 2010, a 162% increase over second quarter 2009. Net loss for the second quarter was $5.1 million, or $0.60 per share, compared to a net loss of $4.3 million and $1.08 per share for the same period last year.

10 Aug 2010

BRAX Fundraising, NFL encourage schools to participate in Back to Football Friday Contest

BRAX Fundraising, an official licensee of the National Football League, has teamed up with the NFL to present the Back to Football Friday Contest. The contest encourages elementary and middle schools across the country to celebrate their favorite NFL teams on Friday, September 10, for a chance to win one of thirty-four $10,000 NFL PLAY 60 health and wellness grants, and a visit from an NFL player.

7 Aug 2010

U.S. Senate passes I-ACT to enable patients with rare disease to participate in clinical trials

The U.S. Senate last night passed the "Improving Access to Clinical Trials Act" (I-ACT), a bipartisan piece of legislation championed by the Cystic Fibrosis Foundation, its advocates and 120 other health advocacy organizations.The legislation enables patients with rare diseases to participate in clinical trials without losing eligibility for public healthcare benefits.

7 Aug 2010

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Study finds new therapeutic target for polycystic kidney disease

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

DARA BioSciences presents KRN5500 study results at World Congress on Pain

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Research finds immune system mechanism to minimize collateral damage

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

NIH awards $1.2 million EUREKA grant to study protein misfolding

Pfizer enters agreement to acquire FoldRx Pharmaceuticals

Luminex launches FDA-cleared xTAG Cystic Fibrosis 60 Kit v2 diagnostic test

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

LevPharm to distribute Innovotech's bioFILM PA- test in Israel

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Aradigm reports net loss of $4.1M for second-quarter 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

GenMark second-quarter revenues increase 162% to $651,000

BRAX Fundraising, NFL encourage schools to participate in Back to Football Friday Contest

U.S. Senate passes I-ACT to enable patients with rare disease to participate in clinical trials

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in